New data presented for the first time today at the 42nd annual meeting of the European Association for the Study of Diabetes (EASD) in Copenhagen demonstrated in patients off therapy at randomization a significant mean placebo-subtracted reduction in HbA1c of 2.1% (primary analysis of all patients treated, p
Recent Posts
- EntreMed Shows Increased Survival With MKC-1 In Preclinical Renal Cell Cancer Model
- Black Raspberries May Help Prevent Esophageal Cancer
- Drug May Help Pregnant Women With Insulin Resistance
- Synta Pharmaceuticals Announces Updated Elesclomol SYMMETRYSM Data Presented At Melanoma XIII
- First Patients Undergo Surgery In Northwest Biotherapeutics' Phase II Brain Cancer Trial
- Genetic mutation found that is major contributor to type 1 diabetes
- Arnold J. Levine And John Mendelsohn Recognized For Monumental Achievements In Basic And Translational Cancer Research
- Glybera(TM) Shows Long-Term Health Benefits
- ADHA Applauds W.K. Kellogg Foundation Report Supporting Use Of Dental Therapist And Dental Therapist-Hygienist Oral Health Providers
- Annual Meeting Of American Academy Of Periodontology To Feature Keynote From Prominent Cardiologist
- OrBIT Study Long Term Results Show Sustained Therapeutic Effect Of Percutaneous Tibial Nerve Stimulation At 12 Months